Evaluationsub-chronic toxicity of the drug Iverlong 2
The aim of the research was to determine the subchronic toxicity of the prolonged action antiparasitic drug Iverlong 2. This drug relates to integrated antiparasitic long-acting drugs produced in the form of the solution forinjections, its active substances are ivermectin, praziquantel and auxiliaries. For the experiment 3 groups of rats were formed on the unique principle - males, weighing 200-230 g. Every group contained 15 rats. Animals of the first test group were getting Iverlong 2 at a dose of 86 mg/200g (1/10 of LD50) intraperitoneally daily for 14 days. Animals of the second test group were getting Iverlong 2 at a dose of 8.6 mg/200 g (1/100 of the LD50) in the same mode. During the research of sub-chronic toxicity of Iverlong 2 it was found that 1/10 dose of the drug (86mg / 200g) from the LD50 is toxic in the study of the functional state of the liver at 14 day of administration. There was an increase indicator of liver enzymes and decreased total protein. That indicates imperceptible hepatotoxicity of increaseddrug doses in chronic experiment. An increase of indicator liver enzymes and decrease of total protein had been observed. When the drug at a dose of 86 mg / kg waslong-term administrated, a decrease in renal functional activity was observed, the increase in concentration of creatinine and urea, reduction of the specific gravity of urine proved it. Parameters ofclinical analysis of peripheral blood throughout the experiment in the animals of experimental groups did not differ significantly from those of the control animals. All the indicators normalized in 21 days after cessation of the introduction of the drug. Iverlong 2 does not lead to statistically significant changes in indicators of the central nervous system of the experimental animals.